best365网页版登录·(中国区)官方网站

best365网页版登录·(中国区)官方网站

BIOQINGLAM
Leader in Transdermal Technology Research and Development and Solution for Soluble Microneedle Drug Delivery
BIOQINGLAM is a R&D-driven enterprise focusing on the R&D and industrialization of soluble microneedle drug delivery technology. Microneedle drug delivery technology is a complicated system engineering, involving MEMS, coating process, pharmaceutics, materials science, molecular biology, biochemistry, industrial engineering and other multidisciplinary and multi-field technologies. Application of the microneedle drug delivery technology requires strong capabilities of system integration. BIOQINGLAM team has 15 years of experience in project R&D and industrialization, and firmly practice the concept of the Design for Six Sigma (DFSS). In 2021, we got successes from the research of the soluble microneedles delivery for gene drugs in cooperation with our customers. At present, we are working with several listed pharmaceutical companies to develop microneedle-drugs, which include genetic vaccines, inactivated vaccines, proteins, polypeptide and chemical drugs. We combine closely research and development with industrialization, and have built and put into operation a GMP workshop dedicated to R&D of drugs. We provide technical outputs to our customers that can only be successfully industrialized.
"It starts small."
Our Team
  • Lin Jiang
    Founder of the Company / Doctor of Organic Chemistry, Chinese Academy of Sciences
    He is the founder of the company, doctor of organic chemistry from Chinese Academy of Sciences, leader of research and development and industrialization of transdermal drug delivery technology of soluble microneedles, and the founder, executive director and general manager of Shenzhen Qinglan Biotechnology Co., Ltd., and has obtained more than 40 national authorized invention patents. He focuses on the research and development on microneedle delivery vaccine and the solutions for new drug research and development of microneedle patches.
    More
  • Xingyou Li
    Quality Operation Director
    Bachelor of Science in Analytical Chemistry, Department of Chemistry, Jilin University.
    He has set up 3 testing laboratories and participated in the hardware and GMP software construction of 3 pharmaceutical enterprises. He has 16 years of laboratory experience and 22 years of quality management experience in the pharmaceutical industry. Involving ISO 9001 certification, CNAS accreditation, WHO-PQ certification, GMP certification at home and abroad, etc., he has rich experience in GMP auditing.
    Many years of experience in biological products, traditional Chinese medicine preparations, chemical preparations and other fields. The pharmaceutical dosage forms involved are: sterile lyophilized powder injection, small volume injection, tablets, capsules, soft capsules, granules, etc.
    Participated in the quality research of multiple biologics projects and obtained two drug clinical research approvals.
    Organized and completed two drug production technology transfer projects, and obtained 6 drug supplement application approvals.
    More
  • Venus Poon
    R&D Director
    She has more than ten years experience in the R&D, registration, and management of new drug preparations, she has been responsible for and managed drug research and development and registration from innovative drug preparation research and development, the declaration to full life cycle management in several pharmaceutical companies.
    Familiar with the R&D, application, and registration requirements of innovative drug preparations, also familiar with the registration requirements of biopharmaceutical IND and BLA. Has been responsible for the development, quality research, and registration application of a number of innovative drug preparations.
    Serving as the company's R&D director, responsible for the company's R&D of new drug preparation, and quality research.
    More
Lin Jiang
Xingyou Li
Venus Poon
Principle and advantages of microneedle drug delivery technology
According to the latest professional literature, microneedle technology includes solid needle, hollow needle, coated needle, soluble microneedle and swelling needle. Based on its own research and development practices, BIOQINGLAM is optimistic about the application of soluble microneedle technology in drug delivery and diagnosis. Microneedle drug delivery technology is a practical science and a results-oriented technology.
  • Painless and non-invasive, patient compliance is the highest, user experience is similar to band-aids, no need for professionals' guidance or help, patients could operate it themselves.
  • The dosage is reduced to 1/5 to 1/200 of the dosage of traditional dosage forms ,As the dosage decreases sharply, side effects are negligible.
  • The delivery of vaccine with microneedle patches has been proven to trigger an enhanced immune response and save dose. In addition, microneedle drug delivery has been shown to enhance the pharmacokinetic and pharmacodynamic effects of certain drugs.
  • Microneedling drug delivery is adequate for a wide range of active (therapeutic and vaccine) and inactive compounds, including small molecules, nucleic acids, peptides, proteins, and micro/nanoparticles.
  • The proprietary formulation and manufacturing process have proven that our microneedle patches maintain the stability of their pharmaceutical actives at room temperature, thereby reducing or so far as to eliminate the cold chain.
Cooperative R&D
Microneedle drug delivery technology is a kind of dosage form technology and an innovative way of drug delivery. It is an innovative dosage form juxtaposed with tablets, capsules and injections. All drugs need a dosage form before they can be used by patients. In the past, drug developers could only choose conventional dosage forms such as tablets, capsules and injections. Now, soluble microneedle drug delivery technology has solved the industrialization problem, providing drug developers with a new dosage form.
Cooperators
JUL 2021 Received 10 million yuan (angel round) investment from Beijing Advaccine Biotechnology Co., Ltd.
JUL 2022 Led by Jiaxing TianfuHuasheng Equity Investment Partnership (Limited Partnership), followed by Beijing Advaccine Biotechnology Co., Ltd., received a total of 25 million yuan (pre-A round) investment.
JUN 2023 A round of financing (the 3rd round)
网站地图XML